BPTH: AI 评分 44/100 — AI 分析 (4月 2026)

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. Their DNAbilize platform aims to improve drug delivery, with several drug candidates in clinical trials for various cancers and related metabolic diseases.

Key Facts: Price: $0.05 AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Bio-Path Holdings, Inc. is a biotechnology company specializing in RNAi nanoparticle drug development for oncology, utilizing its proprietary DNAbilize platform. With drug candidates in Phase 1 and 2 clinical trials targeting AML, lymphoma, and solid tumors, Bio-Path seeks to improve treatment efficacy and delivery in the competitive biotechnology landscape.

BPTH是做什么的？

Bio-Path Holdings, Inc., founded in 2007 and based in Bellaire, Texas, is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. The company is dedicated to developing innovative therapies for cancer using its proprietary DNAbilize platform. This platform utilizes P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification designed to protect DNA from enzymatic degradation in vivo, encapsulated within a neutral-charge lipid bilayer. Bio-Path's lead drug candidate, Prexigebersen (BP1001), is currently in Phase 2 clinical trials for the treatment of untreated acute myeloid leukemia (AML). The company is also advancing BP1001-A, which is in Phase 1 clinical trials for solid tumors, including ovarian, endometrial, and pancreatic cancer. Furthermore, BP1001-A is in preclinical development for treating obesity and related metabolic diseases. Other pipeline assets include Liposomal Bcl-2 (BP1002), in Phase 1 clinical trials for refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia, and Liposomal STAT3 (BP1003), in preclinical development for pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path's focus on RNAi technology and nanoparticle drug delivery positions it within the evolving landscape of targeted cancer therapies.

BPTH的投资论点是什么？

Bio-Path Holdings operates in the high-risk, high-reward biotechnology sector, with a focus on RNAi nanoparticle drug development. The company's lead drug candidate, Prexigebersen (BP1001), is in Phase 2 clinical trials for AML, representing a key value driver. Successful trial outcomes and subsequent regulatory approvals could significantly increase the company's value. Further potential lies in the development of BP1001-A and other pipeline assets targeting solid tumors and hematologic malignancies. However, the company faces significant risks associated with clinical trial failures, regulatory hurdles, and the need for substantial capital to fund ongoing research and development. The company's market capitalization is $0.00B as of March 15, 2026.

BPTH在哪个行业运营？

Bio-Path Holdings operates within the biotechnology industry, which is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Bio-Path are focused on developing targeted therapies that offer improved efficacy and reduced toxicity compared to traditional treatments. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in specific cancer indications. Success in this industry requires significant investment in research and development, as well as the ability to navigate complex regulatory pathways.

Biotechnology

Healthcare

BPTH有哪些增长机遇？

Expansion of Prexigebersen (BP1001) into additional AML subtypes: The market for AML therapies is substantial, and Bio-Path could expand the use of Prexigebersen into additional AML subtypes beyond untreated AML. This would require further clinical trials but could significantly increase the drug's market potential. The AML therapeutics market is projected to reach $4.2 billion by 2027, offering a substantial opportunity for Bio-Path.
Advancement of BP1001-A in solid tumor indications: BP1001-A is currently in Phase 1 clinical trials for solid tumors, including ovarian, endometrial, and pancreatic cancer. Successful clinical trial outcomes could lead to regulatory approvals and commercialization in these indications. The global solid tumor market is expected to reach $450 billion by 2030, presenting a significant growth opportunity for Bio-Path.
Development of Liposomal Bcl-2 (BP1002) for lymphoma and CLL: Liposomal Bcl-2 is in Phase 1 clinical trials for refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia. Positive clinical data could lead to further development and commercialization in these hematologic malignancies. The lymphoma and CLL therapeutics market is projected to reach $25 billion by 2028.
Preclinical development of Liposomal STAT3 (BP1003) for various cancers: Liposomal STAT3 is in preclinical development for pancreatic cancer, non-small cell lung cancer, and AML. Successful preclinical studies could lead to clinical trials and potential commercialization in these indications. The market for pancreatic cancer therapeutics is projected to reach $4.5 billion by 2027.
Partnerships and collaborations: Bio-Path could pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's growth prospects. Strategic alliances are common in the biotechnology industry and can significantly de-risk development programs.

Bio-Path Holdings is focused on RNAi nanoparticle drug development for oncology.
The company's lead drug candidate, Prexigebersen (BP1001), is in Phase 2 clinical trials for the treatment of untreated acute myeloid leukemia (AML).
BP1001-A is in Phase 1 clinical trials for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer.
Liposomal Bcl-2 (BP1002) is in Phase 1 clinical trials to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia.
Liposomal STAT3 (BP1003) is in preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.

BPTH提供哪些产品和服务？

Develops RNAi nanoparticle drugs for cancer treatment.
Utilizes the DNAbilize platform for drug delivery.
Conducts clinical trials for various cancer indications.
Focuses on targeted therapies for improved efficacy.
Develops treatments for both hematologic malignancies and solid tumors.
Engages in preclinical research for new drug candidates.

BPTH如何赚钱？

Develops and patents RNAi nanoparticle drug candidates.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approvals from agencies like the FDA.
Potentially commercializes approved drugs or partners with larger pharmaceutical companies.

Patients with cancer, including AML, lymphoma, and solid tumors.
Hospitals and oncology clinics.
Potential pharmaceutical partners for licensing and collaboration agreements.

Proprietary DNAbilize platform for drug delivery.
Patent protection for drug candidates and platform technology.
Clinical trial data demonstrating safety and efficacy.
Expertise in RNAi technology and nanoparticle formulation.

什么因素可能推动BPTH股价上涨？

Ongoing: Phase 2 clinical trial results for Prexigebersen (BP1001) in AML.
Ongoing: Phase 1 clinical trial progress for BP1001-A in solid tumors.
Upcoming: Potential partnerships or collaborations with pharmaceutical companies.
Upcoming: Publication of preclinical data for Liposomal STAT3 (BP1003).
Upcoming: Regulatory updates regarding drug development programs.

BPTH的主要风险是什么？

Ongoing: Clinical trial failures or delays.
Ongoing: Regulatory setbacks or rejection of drug candidates.
Potential: Need for additional capital to fund operations.
Potential: Competition from other cancer therapies.
Potential: Intellectual property challenges or patent infringement.

BPTH的核心优势是什么？

Proprietary DNAbilize platform.
Pipeline of drug candidates in various stages of development.
Focus on targeted therapies for cancer.
Experienced management team.

BPTH的劣势是什么？

Limited financial resources.
Dependence on clinical trial outcomes.
High risk of drug development failure.
OTC market listing.

BPTH有哪些机遇？

Expansion into new cancer indications.
Partnerships with larger pharmaceutical companies.
Advancement of preclinical programs into clinical trials.
Potential for breakthrough therapies in oncology.

BPTH面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles and delays.
Clinical trial failures.
Need for significant capital to fund development.

BPTH的竞争对手是谁？

Unknown — Unknown — (Unknown)

Key Metrics

Price: $0.05 (-5.66%)
MoonshotScore: 44/100

Company Profile

Headquarters: Bellaire, United States
Employees: 10

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bio-Path Holdings, Inc. do?

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It utilizes its proprietary DNAbilize platform to deliver antisense drugs that target and inhibit cancer-causing genes. The company's pipeline includes drug candidates in clinical trials for various hematologic malignancies and solid tumors, aiming to improve treatment outcomes with targeted therapies.

What do analysts say about BPTH stock?

As of March 15, 2026, there is limited analyst coverage available for Bio-Path Holdings, Inc. (BPTH), likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies, including clinical trial outcomes, regulatory approvals, and funding requirements. The stock's beta is -0.28.

What are the main risks for BPTH?

Bio-Path Holdings, Inc. faces significant risks inherent in the biotechnology industry, including the potential for clinical trial failures, regulatory setbacks, and the need for substantial capital to fund ongoing research and development. As an OTC-listed company, BPTH is subject to increased volatility and liquidity risks. Competition from established pharmaceutical companies and the potential for intellectual property challenges also pose threats to the company's success.